Christopher W. Espelin,Elena Geretti,Bart S. Hendriks,Victor Moyo,Joseph G. Reynolds,Thomas Wickham
申请号：
US15598942
公开号：
US20170258903A1
申请日:
2017.05.18
申请国别(地区):
US
年份:
2017
代理人:
摘要：
Methods for treating cancer patients (e.g., cancer patients resistant or intolerant to pertuzumab and ado-trastuzumab emtansine) with HER2-positive tumors are disclosed. The methods comprise administering to a patient a therapeutically effective amount of a combination of a doxorubicin-loaded immunoliposome with a targeting moiety that is an anti-HER2 antibody that is not an inhibitor of HER2 signaling and an anti-cancer therapeutic comprising a doxorubicin-free anti-cancer therapeutic comprising a different anti-HER2 antibody.
